Welcome to our dedicated page for Curis news (Ticker: CRIS), a resource for investors and traders seeking the latest updates and insights on Curis stock.
Curis, Inc. (NASDAQ: CRIS) is a biotechnology company that publicly describes its focus as the development of emavusertib (CA-4948), an orally available small molecule inhibitor of IRAK4 and, in some disclosures, FLT3. The Curis news stream highlights clinical progress, financing events, and corporate updates that shape the company’s development plans and capital position.
News about Curis frequently covers clinical data and study milestones for emavusertib. The company has reported interim results from its frontline AML triplet study (emavusertib with venetoclax and azacitidine), updates from the TakeAim Lymphoma and TakeAim Leukemia Phase 1/2 trials in PCNSL, AML and high-risk MDS, and presentations at major medical meetings such as the American Society of Hematology (ASH), the Society for Neuro-Oncology (SNO), and ASCO. These releases often describe response measures such as minimal residual disease status and safety observations within defined patient cohorts.
Investors following CRIS news will also see financing and capital markets announcements, including registered direct offerings, concurrent private placements of pre-funded and common warrants, and a PIPE financing involving Series B convertible preferred stock and multiple warrant series. Curis’s news has detailed the structure of these transactions, the gross proceeds, and the stated use of funds for research and development, general corporate purposes, and working capital.
Additional news items address corporate and regulatory developments, such as business updates, quarterly financial results, inducement equity grants, conference participation, and Nasdaq listing compliance notices related to market value of listed securities requirements. For readers tracking Curis, the CRIS news page provides an organized view of these clinical, financial, and listing-related disclosures in one place, allowing users to review how trial data, capital raises, and regulatory interactions evolve over time.
Curis (NASDAQ: CRIS) announced the closing of a private placement (PIPE) raising up to $80.8 million in gross proceeds, with initial gross proceeds of approximately $20.2 million to the company, before placement agent fees and offering expenses. The PIPE was led by Nantahala Capital, Stonepine Capital Management, Pointillist Partners, and The Red Hook Fund, and included participation from other new and existing institutional investors as well as members of Curis' management team and board. Laidlaw & Company (UK) Ltd. acted as sole placement agent.
Curis (NASDAQ: CRIS) entered a securities purchase agreement for a private placement (PIPE) expected to raise up to $80.8 million in gross proceeds, including initial gross proceeds of approximately $20.2 million, before placement agent fees and offering expenses.
The financing sells 20,195 shares of Series B convertible preferred stock plus Series A, B and C warrants (each to purchase 26,926,675 shares of common stock or pre-funded equivalents). Each Security is priced at $1,000 and the Warrants have an $0.75 exercise price. Certain company insiders are participating.
Closing is expected on or about January 8, 2026, subject to customary conditions; Series B preferred conversion and Warrant exercisability require stockholder approval and registration rights were agreed for resale registration.
Curis (NASDAQ: CRIS) posted updated clinical data from its frontline Acute Myeloid Leukemia triplet study (CA-4948-104) presented at the 67th ASH Annual Meeting on December 9, 2025. The study adds emavusertib (ema) to venetoclax plus azacitidine in AML patients who were in complete remission but remained MRD-positive.
As of October 12, 2025, 5 of 8 patients (62.5%) achieved undetectable MRD (uMRD), up from 4 of 8 (50%) reported as of July 2, 2025. The company reported no change in safety profile across the updated dataset. The first two cohorts tested ema dosing for 7 or 14 days per 28-day cycle.
Curis (NASDAQ: CRIS) will present clinical and preclinical data on emavusertib (CA-4948), an oral IRAK4 inhibitor, at the 30th Annual Society for Neuro‑Oncology (SNO) Meeting on November 19–23, 2025.
Key presentations: poster and rapid oral presentations on Nov 21–22, 2025 reporting emavusertib plus BTKi clinical data in Primary CNS Lymphoma (PCNSL) and Secondary CNS Lymphoma (SCNSL) by Dr. Christian Grommes, Dr. Lakshmi Nayak and Cecilia Merrigan; and an oral talk on Nov 23, 2025 by Christina von Roemeling on targeting Myddosome signaling in melanoma brain metastases. Times listed are local ET and HT for each session.
Curis (NASDAQ: CRIS) reported third-quarter 2025 results and clinical progress on Nov 6, 2025. The company posted a Q3 net loss of $7.7M ($0.49/share) vs $10.1M a year earlier and revenues of $3.2M. R&D expense fell to $6.4M in Q3. Cash and cash equivalents were $9.1M at Sept 30, 2025, with a runway into Q1 2026; ~12.7M shares outstanding. Operationally, Curis continues enrollment in PCNSL TakeAim (seeking accelerated US/EU filings), filed a Phase 2 CLL protocol (first patient late Q4/early Q1), reported AML triplet MRD data (50% MRD conversion, data cut Jul 2, 2025), and holds orphan designation in PCNSL.
Curis (NASDAQ: CRIS) will report its third quarter 2025 financial and operating results on Thursday, November 6, 2025 at 4:00 p.m. ET. Management will host a conference call and simultaneous webcast the same day at 4:30 p.m. ET.
Participants can join by dialing (800) 836-8184 (U.S.) or (646) 357-8785 (international), via the live audio webcast linked from the company's events & presentations page, and a replay will be available at www.curis.com.
Curis (NASDAQ: CRIS) announced on October 1, 2025 that its independent Compensation Committee approved inducement stock option grants to two new employees totaling 84,750 shares (the "Q4 2025 Inducement Grants").
Each option has an exercise price equal to the closing price of Curis common stock on October 1, 2025, a 10-year term, and vests over four years: 25% at first anniversary of hire and then 6.25% every three months, subject to continued service. The awards were granted outside the company's 2010 Stock Incentive Plan as inducements to accept employment.
Curis (NASDAQ: CRIS), a biotechnology company developing emavusertib (CA-4948), an oral IRAK4 inhibitor, has announced upcoming presentations at two major healthcare conferences in September 2025.
CEO James Dentzer will participate in a fireside chat at the Cantor Global Healthcare Conference on September 5, 2025, at 9:45 am ET, and deliver a company presentation at the H.C. Wainwright Global Investment Conference on September 10, 2025, at 10:00 am ET. Both presentations will be available via webcast on the company's investor relations website.
Curis (NASDAQ: CRIS) reported its Q2 2025 financial results and business updates, focusing on the development of emavusertib, their oral IRAK4 inhibitor. The company reported a net loss of $8.6 million ($0.68 per share), an improvement from $11.8 million loss in Q2 2024. Revenues increased to $2.7 million, up from $2.5 million year-over-year.
Key operational highlights include continued enrollment in the TakeAim Lymphoma study for PCNSL patients, completion of enrollment in the TakeAim Leukemia Phase 1/2 study, and plans to initiate a new clinical study combining emavusertib with BTKi in CLL patients. The company's cash position stands at $10.1 million, with recent offerings extending runway into Q1 2026.
Curis (NASDAQ: CRIS), a biotechnology company developing emavusertib (CA-4948), has scheduled its second quarter 2025 financial results announcement for August 5, 2025, at 8:00 a.m. ET.
The company will host a conference call and webcast at 8:30 a.m. ET on the same day. Participants can join via phone or access the live audio webcast through the company's website. A replay will be available at www.curis.com.
FAQ
What is the current stock price of Curis (CRIS)?
What is the market cap of Curis (CRIS)?
